Cancer patients requiring interruption o
β
Giorgia Saccullo; Alessandra Malato; Simona Raso; Marco Santoro; Valentina Zammi
π
Article
π
2012
π
John Wiley and Sons
π
English
β 779 KB
## Abstract No data are available regarding the management of cancer patients requiring interruption of longβterm vitaminβK antagonist (VKA) therapy. For this purpose, we tested the efficacy and safety of fixed doses of lowβmolecular weight heparin (LMWH) in substitution of VKA because of invasive